Clinical relevance on alzheimer's disease endpoints

Journal of Nutrition, Health and Aging

Volumn 11, Issue 4, 2007, Pages 316-317

  Sampaio, Cristina ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONSENSUS; DEMENTIA; DISABILITY; DISEASE SEVERITY; HEALTH STATUS; HUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHYSICIAN; PRIORITY JOURNAL; RATING SCALE;

EID: 34547200153     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
2. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med 1996;27:485-489.
3. Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med 2001;38:633-638.
4. Bird SB, Dickson EW. Clinically significant changes in pain along the visual analog scale. Ann Emerg Med 2001;38:639-643
5. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord. 2006 Aug;21(8):1200-7.
6. Hsieh YW, Wang CH, Wu SC, Chen PC, Sheu CF, Hsieh CL. Establishing the Minimal Clinically Important Difference of the Barthel Index in Stroke Patients. Neurorehabil Neural Repair. 2007 Mar 9; [Epub ahead of print]
7. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404.
8. Burback D, Molnar FJ, St. John P, Man-Son-Hing M. Key Methodological Features of Randomized Controlled Trials of Alzheimer's Disease Therapy Minimal Clinically Important Difference, Sample Size and Trial Duration. Dement Geriatr Cogn Disord 1999;10: 534-540.
9. Wells G, Beaton D, Shea B et al. Minimal Clinically Important Differences: Review of Methods. J Rheumatol 2001;28:406-12.
10. Cohen J. Statistical power analysis for the behavioural sciences. New York: academic press, 1977.
11. Nice guideline. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. http://guidance.nice.org. uls/TA111 (consulted on March 1, 2007)
12. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2004; 75:677-685.
13. Smith M, Wells J, Borrie M. Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3):133-7.